Page 14 - Simulations Plus News Today

16.02.2023 - Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large agrochemicals company to extend the ...

Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safetyLANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical...

09.02.2023 - Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a quantitative systems pharmacology (QSP) modeling ... Seite 1

Operator: Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Item 2.02 Results of Operations and Financial Condition On January 4, 2023, Simulations Plus, Inc., a California corporation , issued a press release announcing financial results for... | January 4, 2023

Medical modeling and simulation software company Simulations Plus has been awarded a grant from the Food and Drug Administration through a joint proposal with the University of Bath’s Department of Life Sciences.

Project will focus on the development of a modeling simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract Simulations Plus, Inc.

Simulations Plus, Inc. (NASDAQ:NASDAQ:SLP) Q4 2022 Earnings Conference Call October 26, 2022 5:00 PM ET Company Participants Brian Siegel – Hayden IR Shawn O’Connor – Chief Executive...

Conference call to be on Wednesday, October 26, 2022, at 5:00 PM ETLANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close of the financial...

/PRNewswire/ -- The "Global Biosimulation Market Size, Share & Trends Analysis Report by Product (Software, Services), by Application (Drug Development, Drug...